Media Articles Related to Cardene SR (Nicardipine)
Source: MedicineNet Angina Specialty [2013.11.25]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/25/2013 12:00:00 AM
Increased risk of alcohol-related hypertension in individuals who flush after drinking
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2013.11.21]
Excessive drinking is a known risk factor for hypertension. Drinking that results in facial flushing indicates high sensitivity or even intolerance to alcohol. A study of the relationship between drinking and these two conditions has found that drinking-related hypertension has a lower threshold value and higher risk in flushers than in non-flushers.
Some allergy suffers with hypertension may be at increased risk for severe reaction
Source: Allergy News From Medical News Today [2013.11.12]
Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple.
In low-income urban neighborhoods the rates of diabetes, hypertension, heart disease and stroke are much higher
Source: Hypertension News From Medical News Today [2013.11.07]
There is more to the cost of living in a food desert than higher prices for the few fruits and vegetables sold nearby, according to a study by an Indiana University-Purdue University Indianapolis researcher and the Marion County Public Health Department.
Further positive Opsumit (macitentan) data in pulmonary arterial hypertension presented at CHEST 2013
Source: Hypertension News From Medical News Today [2013.10.31]
Actelion (SIX: ATLN) has announced that following the recent FDA approval and positive CHMP opinion for macitentan (Opsumit®) in pulmonary arterial hypertension (PAH), further positive data on the efficacy of macitentan from the SERAPHIN study were presented at CHEST 2013 in Chicago, USA (26-31 October 2013).
Published Studies Related to Cardene SR (Nicardipine)
Development of nicardipine prolonged-release implants after clipping for
preventing cerebral vasospasm: from laboratory to clinical trial. 
We have developed a drug delivery system using a vasodilating drug that can be
implanted intracranially at the time of surgery for aneurysm clipping, without
systemic side effects or side effects associated with long-term intrathecal drug
administration.We have performed three studies (a
single-center study with consecutive patients; a single-center, randomized,
double-blind trial; and a multicenter cooperative study) and have proved that
implantation of NPRIs reduces the incidence of cerebral vasospasm and DINDs and
improves clinical outcome after SAH.
CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. 
INTRODUCTION: Our purpose was to compare the safety and efficacy of food and drug administration (FDA) recommended dosing of IV nicardipine versus IV labetalol for the management of acute hypertension... CONCLUSIONS: Patients treated with nicardipine are more likely to reach the physician-specified SBP target range within 30 minutes than those treated with labetalol.
Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. [2010.11]
INTRODUCTION: Various conservative treatments for Peyronie's disease (PD) have been attempted over the years. Intralesional verapamil injection has been tested in prospective randomized studies, but the effect of this treatment seems insufficient. Nicardipine is a calcium antagonist alternative to verapamil and is reportedly more effective in vitro. AIM: The objective of our study was to evaluate the usefulness of intralesional nicardipine injection as a conservative treatment for PD in the transition period of acute and chronic phase... CONCLUSION: Our findings indicate that intralesional nicardipine injection is clinically effective as a conservative treatment for PD in the transition period of acute and chronic phase. (c) 2010 International Society for Sexual Medicine.
Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. [2009.06]
BACKGROUND: Elevation in cardiac enzymes after percutaneous coronary intervention (PCI) is common and is associated with adverse clinical outcomes. HYPOTHESIS: Administration of intracoronary nicardipine-a calcium channel blocker will reduce cardiac enzyme levels in patients undergoing elective PCI... CONCLUSIONS: In low-risk patients undergoing elective PCI, intracoronary nicardipine administration did not produce a significant cardioprotective effect in reducing postprocedural cardiac enzymes leakage. Copyright (c) 2009 Wiley Periodicals, Inc.
Effect of nicardipine on renal function after robot-assisted laparoscopic radical prostatectomy. [2009.05]
OBJECTIVES: To investigate the renoprotective effect of nicardipine in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALRP) in a prospective trial. Superior visualization of the increasingly performed RALRP requires pneumoperitoneum and extreme head-down tilt, both of which are associated with a decrease in postoperative renal function. Nicardipine causes preferential dilation of the renal arterioles and attenuates renal dysfunction after cardiac surgery... CONCLUSIONS: Continuous infusion of low-dose nicardipine during RALRP seems to offset the deleterious effects of inevitable pneumoperitoneum and extreme head-down tilt on renal function in preserving the eGFR and attenuating the development of renal insufficiency in the immediate postoperative period.
Clinical Trials Related to Cardene SR (Nicardipine)
IV Double and Triple Concentrated Nicardipine for Stroke and ICH [Recruiting]
Hypertension (high blood pressure) can often cause neurological worsening in patients with
stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of
nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of
Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The
purpose of this study is to evaluate safety and efficacy of double or triple concentrated
peripheral intravenous (IV) Nicardipine.
Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine [Recruiting]
The aim of this study is to confirm that URAPIDIL is as efficient and as safe as NICARDIPINE
to correct severe hypertension in pre-eclamptic patients.
- efficacy endpoint : mean arterial blood pressure corrected to 105-125 mmHg after 120
min of study drug administration.
- safety endpoints : clinical, biological and ultrasound observation for any side
effect. All infants will be observed in the neonatology unit (during 48h).
Evaluation of IV Cardene(Nicardipine)and Labetalol Use in the Emergency Department [Recruiting]
Nicardipine Versus Labetalol During Intubation [Recruiting]
The aim of this study was to compare the efficacy of nicardipine and labetalol in
attenuation of cardiovascular responses to endotracheal intubation.
The Effect of Nicardipine on Kidney Function During Orthognathic Surgery Under Hypotensive Anesthesia [Not yet recruiting]
Since nicardipine is known to protect kidney function, nicardipine infusion will result in
better renal parameters measured in this study.